The Apex Times
Above the Noise
Business Wire
BusinessBroadcom’s AVGO Share Performance Lags the Technology Sector, While Analysts Stay PositiveThe Apex TimesBusinessAMD shares slip as investors weigh fresh semiconductor tariff risksThe Apex TimesBusinessAlibaba counters Meta’s open-weight AI push with a laptop-ready model and leaked weights, while download momentum lagsThe Apex TimesBusinessMeta faces scrutiny in California-led trial over claims its Facebook and Instagram were built to be addictiveThe Apex TimesBusinessPalantir shares rise as traders eye an options-based income strategyThe Apex TimesBusinessBroadcom becomes Wall Street’s next checkpoint for whether AI hardware demand can keep running hotThe Apex TimesBusinessLilly’s Mounjaro franchise grows after FDA expands label into heart-risk populationThe Apex TimesBusinessDavid Tepper exits UnitedHealth as focus returns to fair value accountingThe Apex TimesBusinessNvidia shares slip as report says AI cloud financing arrangements have been pausedThe Apex TimesBusinessLockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army trainingThe Apex TimesBusinessSteve Eisman flags a concentration risk in AI demand, pointing to OpenAI and Anthropic’s outsized role in big cloud and software revenueThe Apex TimesBusinessBroadcom faces a proving test in its AI quarter as investors look for custom-chip revenue to land on timeThe Apex TimesBusinessBroadcom’s AVGO Share Performance Lags the Technology Sector, While Analysts Stay PositiveThe Apex TimesBusinessAMD shares slip as investors weigh fresh semiconductor tariff risksThe Apex TimesBusinessAlibaba counters Meta’s open-weight AI push with a laptop-ready model and leaked weights, while download momentum lagsThe Apex TimesBusinessMeta faces scrutiny in California-led trial over claims its Facebook and Instagram were built to be addictiveThe Apex TimesBusinessPalantir shares rise as traders eye an options-based income strategyThe Apex TimesBusinessBroadcom becomes Wall Street’s next checkpoint for whether AI hardware demand can keep running hotThe Apex TimesBusinessLilly’s Mounjaro franchise grows after FDA expands label into heart-risk populationThe Apex TimesBusinessDavid Tepper exits UnitedHealth as focus returns to fair value accountingThe Apex TimesBusinessNvidia shares slip as report says AI cloud financing arrangements have been pausedThe Apex TimesBusinessLockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army trainingThe Apex TimesBusinessSteve Eisman flags a concentration risk in AI demand, pointing to OpenAI and Anthropic’s outsized role in big cloud and software revenueThe Apex TimesBusinessBroadcom faces a proving test in its AI quarter as investors look for custom-chip revenue to land on timeThe Apex TimesBusinessBroadcom’s AVGO Share Performance Lags the Technology Sector, While Analysts Stay PositiveThe Apex TimesBusinessAMD shares slip as investors weigh fresh semiconductor tariff risksThe Apex TimesBusinessAlibaba counters Meta’s open-weight AI push with a laptop-ready model and leaked weights, while download momentum lagsThe Apex TimesBusinessMeta faces scrutiny in California-led trial over claims its Facebook and Instagram were built to be addictiveThe Apex TimesBusinessPalantir shares rise as traders eye an options-based income strategyThe Apex TimesBusinessBroadcom becomes Wall Street’s next checkpoint for whether AI hardware demand can keep running hotThe Apex TimesBusinessLilly’s Mounjaro franchise grows after FDA expands label into heart-risk populationThe Apex TimesBusinessDavid Tepper exits UnitedHealth as focus returns to fair value accountingThe Apex TimesBusinessNvidia shares slip as report says AI cloud financing arrangements have been pausedThe Apex TimesBusinessLockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army trainingThe Apex TimesBusinessSteve Eisman flags a concentration risk in AI demand, pointing to OpenAI and Anthropic’s outsized role in big cloud and software revenueThe Apex TimesBusinessBroadcom faces a proving test in its AI quarter as investors look for custom-chip revenue to land on timeThe Apex TimesBusinessBroadcom’s AVGO Share Performance Lags the Technology Sector, While Analysts Stay PositiveThe Apex TimesBusinessAMD shares slip as investors weigh fresh semiconductor tariff risksThe Apex TimesBusinessAlibaba counters Meta’s open-weight AI push with a laptop-ready model and leaked weights, while download momentum lagsThe Apex TimesBusinessMeta faces scrutiny in California-led trial over claims its Facebook and Instagram were built to be addictiveThe Apex TimesBusinessPalantir shares rise as traders eye an options-based income strategyThe Apex TimesBusinessBroadcom becomes Wall Street’s next checkpoint for whether AI hardware demand can keep running hotThe Apex TimesBusinessLilly’s Mounjaro franchise grows after FDA expands label into heart-risk populationThe Apex TimesBusinessDavid Tepper exits UnitedHealth as focus returns to fair value accountingThe Apex TimesBusinessNvidia shares slip as report says AI cloud financing arrangements have been pausedThe Apex TimesBusinessLockheed Martin logs second successful flight test of its new JR3 rocket for lower-cost Army trainingThe Apex TimesBusinessSteve Eisman flags a concentration risk in AI demand, pointing to OpenAI and Anthropic’s outsized role in big cloud and software revenueThe Apex TimesBusinessBroadcom faces a proving test in its AI quarter as investors look for custom-chip revenue to land on timeThe Apex Times
Back to front
Moderna and Merck report late-stage win for personalized melanoma vaccine with Keytruda
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 28, 12:32 PM EDT

Moderna and Merck report late-stage win for personalized melanoma vaccine with Keytruda

The companies said their Phase 3 trial of intismeran plus Merck’s Keytruda met its stated goals in a study of 1,137 patients.

2 min readEditor-approved Apex article

Moderna and Merck & Co. said their personalized cancer vaccine program produced positive late-stage results when paired with Keytruda in melanoma, a combination that targets tumors using a patient-specific approach while relying on an immune checkpoint drug to amplify the response.

In an Aug. 19, 2026 update reported by Yahoo Finance, Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) said their Phase 3 study met its goals for intismeran, Moderna’s personalized melanoma vaccine, in combination with Keytruda. The trial enrolled 1,137 patients, according to the report.

Intismeran is designed to tailor the immune stimulus to an individual’s melanoma, an approach intended to help the body recognize tumor-specific targets more effectively than one-size-fits-all therapies. Keytruda, Merck’s anti-PD-1 therapy, is widely used across several cancers and works by releasing the brakes on T-cells.

The companies did not provide, in the published item, the specific clinical endpoints that were achieved, the magnitude of benefit, or the statistical thresholds used to define success. The report also did not break out efficacy results by patient subgroup or summarize detailed safety findings.

Moderna has built its broader oncology strategy around personalized messenger RNA (mRNA) platforms, where genetic instructions are delivered into the body to prompt an immune response against selected targets. For partners, the strategy can lower some biological uncertainty by combining individualized immune activation with established oncology backbones such as PD-1 blockade.

For Merck, the reported result sits within a competitive push in melanoma and other solid tumors, where the field has shifted toward combinations that combine immune stimulation with checkpoint inhibition. Keytruda’s role in the program underscores that Merck is looking to extend and defend its immunotherapy franchise by pairing it with new modalities rather than relying on monotherapy.

Still, important details were not included in the Yahoo Finance post. The companies did not specify whether the trial met primary endpoints, key secondary endpoints, or both, nor did it disclose hazard ratios, survival curves, response rates, or adverse-event rates in the text reviewed here.

What to watch next is how Moderna and Merck describe the trial in full, including the primary efficacy measures, the durability of responses, and the tolerability profile of the combination. Additional disclosures around regulatory plans and timelines would also clarify whether the companies anticipate filing submissions based on the Phase 3 outcome.

Why It Matters

  • A Phase 3 win, if confirmed in full results, could strengthen the case for personalized mRNA vaccines as an addition to checkpoint inhibitor regimens in melanoma.
  • The combination of intismeran with Keytruda suggests Merck may be seeking incremental expansion of Keytruda’s role into tumor-specific or individualized immune strategies.
  • Melanoma is a competitive immuno-oncology market, so positive late-stage data could shift expectations for how future standards of care are built.
  • Investors and clinicians will likely focus next on the exact endpoints met, the size of benefit, and whether safety and tolerability support broader use.

Sources

Key Facts

  • Moderna and Merck said a Phase 3 trial of their personalized melanoma vaccine intismeran plus Keytruda met the study’s stated goals, according to a Yahoo Finance report.
  • The Phase 3 study enrolled 1,137 patients, the report said.
  • Intismeran is a personalized melanoma vaccine developed by Moderna.
  • Keytruda is Merck’s PD-1 inhibitor used as the combination backbone in the program.
  • The announcement referenced an Aug. 19, 2026 update, as reported by Yahoo Finance.

Healthcare Related

Aug 28, 1:17 PM EDT
The Apex Times

David Tepper exits UnitedHealth as focus returns to fair value accounting

The hedge-fund manager’s sale of his UnitedHealth Group position is prompting investors to re-check how the company measures and reports fair value assets and liabilities, even as the broader healthcare giant continues to operate on steady core fundamentals.

David Tepper exits UnitedHealth as focus returns to fair value accounting
The Apex Times
Aug 28, 11:17 AM EDT
The Apex Times

Pfizer shares steady while BioNTech stumbles after colorectal cancer vaccine trial failure

BioNTech’s colorectal cancer vaccine trial collapsed in Phase 2, a setback that pressured peer stocks including Moderna and weighed on investors’ expectations for mRNA oncology programs. Pfizer, which also has a stake in mRNA vaccine development through collaborations, was reported to hold roughly flat on the day.

Pfizer shares steady while BioNTech stumbles after colorectal cancer vaccine trial failure
The Apex Times